Korean J Pancreas Biliary Tract.  2016 Jul;21(3):128-137. 10.15279/kpba.2016.21.3.128.

Optimal Treatment of Advanced Pancreatic Neuroendocrine Tumor

• Kim YS
• Cho JH

• KMID: 2448526
• DOI: http://doi.org/10.15279/kpba.2016.21.3.128

Abstract

Pancreatic neuroendocrine tumors (pNETs) are diverse diseases with different prognosis. Among available various therapeutic options, curative resection should be considered for localized tumors and in some selected cases of metastatic disease. Somatostatin analogs are used to control hormonal symptoms and also effective to inhibit the tumor progression in specific settings. The molecular targeted agents such as sunitinib and everolimus are efficacious treatments for metastatic WHO grade 1/2 pNETs. Chemotherapy is generally used in highly symptomatic and rapidly growing pNETs such as WHO grade 3. In addition, local ablative therapy should be considered in patients with hepatic predominant unresectable metastatic pNETs, and peptide receptor radionucleotide therapy, which is unavailable in Korea, could be considered after failure of initial medical therapy. The most important of all is a multidisciplinary approach to pNETs. This is essential to optimal management of pNETs regarding the diverse disease nature

Keyword

Pancreas neuroendocrine tumor; Treatment; Prognosis

MeSH Terms

Drug Therapy
Everolimus
Humans
Korea
Neuroectodermal Tumors, Primitive
Neuroendocrine Tumors*
Prognosis
Receptors, Peptide
Somatostatin
Everolimus
Receptors, Peptide
Somatostatin